STOCK TITAN

MANNKIND (MNKD) SEC Filings, Mar-Apr 2026

MNKD NASDAQ

MannKind Corporation filings document formal disclosures for a Nasdaq-listed biopharmaceutical company focused on inhaled and drug-device therapies. Its 8-K reports furnish operating results and business updates for Afrezza, Furoscix and pipeline programs, while also recording capital-structure events such as convertible-note settlement and material collaboration agreements involving the Technosphere platform.

The filing record also includes acquisition-related disclosures for the completed scPharma transaction, including acquired-business financial statements and pro forma combined financial information. MannKind proxy materials address annual meeting matters, executive compensation and equity-award information, and other governance subjects tied to its common stock.

Rhea-AI Summary

MannKind Corp Chief Financial Officer Christopher B. Prentiss reported a routine tax-withholding share disposition. On April 22, 2026, 12,267 shares of common stock at $2.74 per share were withheld to cover taxes on Restricted Stock Units that vested from a grant dated May 15, 2024. After this, he directly held 338,924 shares, including 2,337 shares acquired through the Employee Stock Purchase Plan on December 31, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.59%
Tags
insider
-
ARS
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
annual report
-
Rhea-AI Summary

MannKind Corporation is asking stockholders to vote at its 2026 Annual Meeting, held virtually on May 20, 2026, on three key items: electing nine directors, approving executive pay on an advisory basis, and ratifying Deloitte & Touche LLP as auditor for 2026.

Stockholders of record on March 23, 2026, when 308,795,777 common shares were outstanding, may vote online before or during the meeting. The Board unanimously recommends voting FOR all director nominees, FOR the say‑on‑pay proposal, and FOR Deloitte’s ratification.

The proxy describes MannKind’s governance structure, including an independent chair, fully independent board committees, an anti‑corruption and insider‑trading policy, and director stock ownership guidelines. Non‑employee directors receive cash retainers plus annual restricted stock unit awards that generally vest immediately but are delivered after board service ends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
proxy
Rhea-AI Summary

MannKind Corp — Amendment No. 4 to a Schedule 13G/A filed by The Vanguard Group reports beneficial ownership of 0 shares representing 0% of Common Stock. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538 that prompted disaggregated reporting by certain Vanguard subsidiaries. The report is signed by Ashley Grim on March 27, 2026, and states Vanguard entities have the right to receive dividends or proceeds for managed accounts, while no single outside person holds more than 5%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
ownership
-
Rhea-AI Summary

MannKind Corp’s Chief Financial Officer Christopher B. Prentiss received new equity awards. He was granted 221,000 performance-based restricted stock units, each representing a right to one share of common stock, and 217,000 employee stock options with a $2.44 exercise price, all held directly.

The performance units vest on January 15, 2029, with actual payout from 0% to 300% of the 221,000-share target based on MannKind’s total shareholder return from April 1, 2026 through December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index. The options vest 25% on March 23, 2027 and then 1/16 quarterly until fully vested, and expire on March 23, 2036.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

MannKind Corp Chief Executive Officer Michael Castagna received new equity compensation awards. He was granted 796,000 performance-based restricted stock units, each representing the right to receive one share of common stock. The actual shares that vest on January 15, 2029 can range from 0% to 300% of this target, based on MannKind’s total shareholder return from April 1, 2026 to December 31, 2028 versus the Russell 3000 Pharmaceutical & Biotechnology Index.

He was also granted stock options for 782,000 shares of common stock at an exercise price of $2.4400 per share, expiring on March 23, 2036. These options vest 25% on March 23, 2027 and the remaining portion in equal quarterly installments over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
Rhea-AI Summary

MannKind Corp reported new equity awards for EVP Technical Operations Sanjay R. Singh. He received 221,000 performance-based restricted stock units, each tied to one common share, that vest on January 15, 2029 with payout ranging from 0% to 300% of target based on relative total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028. He was also granted options on 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and the remainder in equal quarterly installments through 2031, expiring March 23, 2036. These are compensation-related grants, not open-market trades.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

MannKind Corporation’s Chief Medical Officer, Ajay Ahuja, reported new equity awards. He received 221,000 performance-based restricted stock units, each representing a right to one share of common stock. These units vest on January 15, 2029, with the actual payout ranging from 0% to 300% of the target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.

He was also granted options on 217,000 shares of common stock at an exercise price of $2.44 per share. These options vest 25% on March 23, 2027, with the remaining 75% vesting in 1/16th increments quarterly, and expire on March 23, 2036. All positions are held directly and reflect compensation awards rather than market purchases or sales.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
-
Rhea-AI Summary

MannKind Corp granted Chief People & Workplace Officer Stuart A. Tross new equity awards. He received 221,000 performance-based restricted stock units, each representing the right to one share of common stock. These units vest on January 15, 2029, with the payout from 0% to 300% of target based on MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 through December 31, 2028.

He was also granted 217,000 stock options with a $2.44 exercise price, expiring on March 23, 2036. These options vest 25% on March 23, 2027, with the remaining 75% vesting in equal quarterly installments over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider
Rhea-AI Summary

MannKind Corp EVP and General Counsel David Thomson reported equity awards, not open-market trades. He received 221,000 performance-based restricted stock units, each representing a contingent right to one share of common stock.

The performance units vest on January 15, 2029, with payout tied to MannKind’s total shareholder return versus the Russell 3000 Pharmaceutical & Biotechnology Index from April 1, 2026 to December 31, 2028. Payout ranges from 0% to 300% of the 221,000-target based on percentile rankings.

Thomson was also granted stock options for 217,000 shares at an exercise price of $2.44 per share, vesting 25% on March 23, 2027 and then 1/16 quarterly through March 23, 2031.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
insider

FAQ

How many MANNKIND (MNKD) SEC filings are available on StockTitan?

StockTitan tracks 91 SEC filings for MANNKIND (MNKD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for MANNKIND (MNKD)?

The most recent SEC filing for MANNKIND (MNKD) was filed on November 19, 2026.